[Retracted] Comparison of Efficacy and Safety of TACE Combined with Microwave Ablation and TACE Combined with Cryoablation in the Treatment of Large Hepatocellular Carcinoma
Table 1
Comparison of baseline characteristics of study patients.
Characteristics
T-MWA group
T-CRA group
P-value
n = 41
n = 40
Age(years)
57.3 ± 9.81
59.70 ± 6.66
0.568
＞58
21(51.2)
24(60.0)
≤58
20(48.8)
16(40.0)
Gender
0.585
Male
28(68.3)
24(60.0)
Female
13(31.7)
16(40.0)
PS
0.858
0
21(51.1)
21(52.5)
1
18(43.9)
16(40.0)
2
2(4.9)
3(7.5)
Etiology
0.513
HBV
36(87.8)
32(80.0)
Other
5(12.2)
8(20.0)
Cirrhosis
0.478
Yes
29(70.7)
32(80.0)
No
12(29.3)
8(20.0)
Tumor number
0.74
Single
19(46.3)
21(52.5)
Multiple
22(53.7)
19(47.5)
Child-Pugh class
1.000
A
32(78.0)
32(80.0)
B
9(22.0)
8(20.0)
AFP level (ng/ml)
0.719
≤400
23(56.1)
25(62.5)
>400
18(43.9)
15(37.5)
PVTT statue
0.941
Yes
12(29.3)
13(32.5)
No
29(70.7)
27(67.5)
ALT (U/L)
27.00 [20.00,44.00]
27.50 [21.00,48.00]
0.688
AST (U/L)
37.00 [28.00,45.00]
35.50 [26.75,47.25]
0.932
Albumin (g/L)
38.60(4.49)
37.24(4.98)
0.199
Total bilirubin (μmol/L)
17.30 [13.30,23.90]
15.00 [11.43,21.33]
0.236
Note. T-MWA: TACE Combined With microwave ablation; T-CRA: TACE Combined With radiofrequency ablation.
